Latest News & Features
Biotechnology
Activist group No Patents on Seeds has filed an opposition against a patent on lettuce, owned by Dutch food supplier Rijk Zwaan Zaadteelt. 7 March 2019
Americas
The US Court of Appeals for the Federal Circuit yesterday, March 6, refused to rehear a decision which found Allergan and the Saint Regis Mohawk Tribe’s patents for dry-eye treatment Restasis (cyclosporine ophthalmic emulsion) are invalid. 7 March 2019
Europe
The EU General Court today, March 6, rejected an appeal against an European Union Intellectual Property Office decision to reject the registration of a mark formerly owned by Allergan. 6 March 2019
Americas
Scott Gottlieb, commissioner of the US Food and Drug Administration, resigned from his post yesterday, March 5, with plans to step down in the next month. 6 March 2019
Americas
The Information Technology and Innovation Foundation think tank has called on the US National Institutions of Health to maintain IP protection amid calls to “break” patents in order to lower drug prices. 5 March 2019
Big Pharma
An opinion on whether a supplementary protection certificate can be granted to an owner of a drug patent when the marketing authorisation is held by a third party is overdue, lawyers told LSIPR. 5 March 2019
Big Pharma
The UK Competition and Markets Authority has provisionally found that pharmaceutical companies Auden Mckenzie and Waymade engaged in anti-competitive behaviour relating to hydrocortisone tablets. 4 March 2019
Americas
The US International Trade Commission has begun an investigation into Daewoong Pharmaceuticals of South Korea and California-based Evolus, following a complaint from Allergan. 4 March 2019
Big Pharma
The patents division of the English High Court has found that a patent owned by Genentech is invalid and denied the biotechnology company’s application for a supplementary protection certificate. 1 March 2019
Americas
The US Federal Trade Commission concluded a ten-year pay-for-delay suit yesterday, with AbbVie agreeing not to enter certain settlements in patent cases that delay market entry of generic drugs. 1 March 2019